In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Molecular Diagnostics--From Tools to Tests

Executive Summary

Instrument makers have made big money off the genomics revolution. But as the research market slows, companies are looking for new business opportunities. One area ripe for development: the molecular diagnostics market.
Advertisement

Related Content

Taking Stock Of Qiagen
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q2 2008
ProGenTech Raises $21 million
Embracing Early-Stage Platform Opportunities at Polaris Ventures
Claros Diagnostics Inc.
Deal Statistics Quarterly, Q2 2006
In Vivo and In Vitro Diagnostics Converge: Siemens buys DPC
The New Diagnostics Companies
Problems With Biomarkers: A Tale of Three Drugs
Inside Applera: Celera Genomics Becomes Applied Bio's Diagnostics Angel

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002763

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel